Dickson, Mark A.

Publications

Sort by

Co-Author Network

selected publications

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 131
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 15
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 414
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The oncologist. 2018 Academic Article GET IT
Times cited: 15
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational new drugs. 2018 Academic Article GET IT
Times cited: 33
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. 2018 Academic Article GET IT
Times cited: 33
ATRX is a regulator of therapy induced senescence in human cells. Nature communications. 2017 Academic Article GET IT
Times cited: 57
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European journal of cancer. 2017 Academic Article GET IT
Times cited: 46
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 107
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of cancer research and clinical oncology. 2016 Academic Article GET IT
Times cited: 11
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nature communications. 2016 Academic Article GET IT
Times cited: 74
Liposarcoma: Multimodality Management and Future Targeted Therapies. Surgical oncology clinics of North America. 2016 Information Resource GET IT
Times cited: 106
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 129
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine Leiomyosarcoma. Sarcoma. 2016 Academic Article GET IT
Times cited: 10
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity. Cancer science. 2016 Academic Article GET IT
Times cited: 17
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Article GET IT
Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. Pediatric blood & cancer. 2015 Information Resource GET IT
Times cited: 42
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. The oncologist. 2015 Academic Article GET IT
Times cited: 23
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. European journal of cancer. 2015 Academic Article GET IT
Times cited: 80
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 862
Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology. 2015 Academic Article GET IT
Times cited: 44
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. The American journal of surgical pathology. 2015 Academic Article GET IT
Times cited: 187
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015 Academic Article GET IT
Times cited: 50
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015 Academic Article GET IT
Times cited: 105
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Investigational new drugs. 2014 Academic Article GET IT
Times cited: 17
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human pathology. 2014 Academic Article GET IT
Times cited: 242
Systemic treatment options for radiation-associated sarcomas. Current treatment options in oncology. 2014 Information Resource GET IT
Times cited: 4
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Academic Article GET IT
Times cited: 361
Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. Leukemia research reports. 2014 Academic Article GET IT
Times cited: 17
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 92
High-risk features in radiation-associated breast angiosarcomas. British journal of cancer. 2013 Academic Article GET IT
Times cited: 58
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 134
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 360
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2013 Academic Article GET IT
Times cited: 176
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Academic Article GET IT
Times cited: 88
The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 83
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). British journal of cancer. 2011 Academic Article GET IT
Times cited: 229
A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 131
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational new drugs. 2010 Academic Article GET IT
Times cited: 33
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 25
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 48
Development of cell-cycle inhibitors for cancer therapy. Current oncology (Toronto, Ont.). 2009 Academic Article GET IT

more ...

less ...

Background

education and training

M.D., Columbia University College of Physicians and Surgeons 2003
A.B., Harvard College 1999

Contact

full name

Mark A. Dickson

VIVO Weill Cornell Medical College

Mark A. Dickson Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name